Skip to main content

Table 1 Clinical research of targeting GLS [127]

From: Role of glutamine and its metabolite ammonia in crosstalk of cancer-associated fibroblasts and cancer cells

Mainly targets ClinicalTrials.gov Identifier Phase First posted Drug Combination drugs
TNBC, NSCLC, renal cell carcinoma NCT02071862 1 2014 CB-839 (Telaglenastat)
CRC NCT03263429 1/2 2017 CB-839 Panitumumab and irinotecan
AML NCT03047993 1/2 2017 CB-839 Azacitidine
Hematological tumors NCT02071888 1 2014 CB-839
Clear cell renal cell carcinoma, melanoma, NSCLC NCT02771626 1/2 2016 CB-839 Nivolumab
NSCLC, CRC NCT03965845 1/2 2019 CB-839 Palbociclib
Clear cell renal cell carcinoma, TNBC NCT03875313 1/2 2019 CB-839 Talazoparib
NSCLC NCT04265534 2 2020 CB-839 Pembrolizumab
TBNC NCT03057600 2 2017 CB-839 Paclitaxel-carboplatin
Metastatic prostate cancer NCT04824937 2 2021 CB-839
AML, ALL NCT02071927 1 2018 CB-839 Azacitidine
Ovarian cancer NCT03944902 1 2019 CB-839 Niraparib
Advanced renal cell carcinoma, metastatic renal cell carcinoma NCT03428217 2 2018 CB-839 Cabozantinib
Malignant peripheral nerve sheath tumors NCT03872427 2 2019 Telaglenastat hydrochloride
Leptomeningeal neoplasm, metastatic lung non-small cell carcinoma, metastatic malignant neoplasm in the brain NCT04250545 1 2020 Telaglenastat hydrochloride
Plasma cell myeloma NCT03798678 1 2019 Telaglenastat hydrochloride Carfilzomib dexamethasone
Astrocytoma NCT03528642 1 2019 Telaglenastat hydrochloride Temozolomide
NSCLC NCT03831932 1 2019 Telaglenastat hydrochloride Osimertinib
  1. TNBC triple negative breast cancer, NSCLC non-small cell lung cancer, CRC colorectal carcinoma, AML acute myeloid leukemia, ALL acute lymphocytic leukemia